Total Funding
69
55
Total FundingPost-IPO Equity raised
Growth Score
-12 pts
Heat Score
-26 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
9379
Candel Therapeutics develops cancer immunotherapies designed to improve the lives of cancer patients and their families.
- Stephen Rocamboli: Chief Business Officer
Estuardo Aguilar-Cordova: Founder and CSOPast Role: Candel Therapeutics, Chairman and Chief Executive Officer
About the Company
Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate
cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.
